Immunovant, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Immunovant, Inc. (IMVT), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are IMVT insiders buying or selling?
In the last 12 months, Immunovant, Inc. insiders reported 1 open-market purchase ($350.0M) and 38 sales ($16.1M) — net buying of $333.9M. Since November 2019, Trabud has recorded 204 Form 4 filings for IMVT: 25 buys ($784.9M) and 179 sells ($42.3M).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $350.0M by Roivant Sciences Ltd. (Director, 10% Owner) on Dec 12, 2025. SEC ↗
- The most recent open-market purchase was reported on Dec 12, 2025 (10 months ago).
Key Statistics (November 2019 – Oct 9, 2026)
Total Form 4 filings
204
SEC EDGAR
Insider filers
19
Insider buys (25)
$784.9M
Insider sells (179)
$42.3M
Insider sentiment
Net buyingNet insider flow of $742.6M in net buying since November 2019, and $333.9M in net buying over the last 12 months.
Recent IMVT insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 9, 2026 | Jay S Stout | Chief Technology Officer | Sale | 3.8K | $32.06 | $122.1K | SEC ↗ |
| Oct 9, 2026 | Christopher Van Tuyl | Chief Legal Officer | Sale | 1.3K | $32.06 | $42.5K | SEC ↗ |
| Oct 9, 2026 | Melanie Gloria | Chief Operating Officer | Sale | 2.2K | $32.06 | $71.8K | SEC ↗ |
| Oct 5, 2026 | Eric Venker | Chief Executive Officer | Sale | 3.5K | $34.11 | $119.6K | SEC ↗ |
| Sep 25, 2026 | Christopher Van Tuyl | Chief Legal Officer | Sale | 2.8K | $36.36 | $103.5K | SEC ↗ |
| Aug 28, 2026 | Atul Pande | Director | Sale | 1.5K | $43.27 | $64.9K | SEC ↗ |
| Aug 21, 2026 | Melanie Gloria | Chief Operating Officer | Sale | 3.1K | $44.16 | $135.0K | SEC ↗ |
| Jul 24, 2026 | Atul Pande | Director | Sale | 1.5K | $39.80 | $59.7K | SEC ↗ |
| Jul 24, 2026 | Tiago Girao | Chief Financial Officer | Sale | 6.8K | $38.69 | $263.0K | SEC ↗ |
| Jul 24, 2026 | Jay S Stout | Chief Technology Officer | Sale | 2.9K | $38.69 | $110.5K | SEC ↗ |
| Jul 6, 2026 | Eric Venker | Chief Executive Officer | Sale | 3.1K | $38.48 | $119.0K | SEC ↗ |
| Jun 26, 2026 | Melanie Gloria | Chief Operating Officer | Sale | 17.7K | $38.31 | $678.6K | SEC ↗ |
| Jun 26, 2026 | Jay S Stout | Chief Technology Officer | Sale | 40.0K | $38.31 | $1.5M | SEC ↗ |
| Jun 26, 2026 | Christopher Van Tuyl | Chief Legal Officer | Sale | 17.8K | $38.31 | $682.9K | SEC ↗ |
| Jun 26, 2026 | Tiago Girao | Chief Financial Officer | Sale | 10.0K | $38.46 | $384.6K | SEC ↗ |
| Jun 26, 2026 | Atul Pande | Director | Sale | 1.5K | $38.01 | $57.0K | SEC ↗ |
| Jun 22, 2026 | Christopher Van Tuyl | Chief Legal Officer | Sale | 2.6K | $35.39 | $93.2K | SEC ↗ |
| Jun 16, 2026 | Atul Pande | Director | Sale | 1.5K | $34.02 | $51.0K | SEC ↗ |
| May 29, 2026 | Andrew J. Fromkin | Director | Sale | 222.0K | $33.51 | $7.4M | SEC ↗ |
| May 22, 2026 | Melanie Gloria | Chief Operating Officer | Sale | 3.1K | $32.45 | $101.1K | SEC ↗ |
| May 21, 2026 | Atul Pande | Director | Sale | 6.0K | $32.00 | $192.0K | SEC ↗ |
| May 1, 2026 | Robert Graham Susman | Director | Sale | 2.5K | $27.17 | $68.0K | SEC ↗ |
| Apr 24, 2026 | Tiago Girao | Chief Financial Officer | Sale | 25.8K | $29.62 | $763.0K | SEC ↗ |
| Apr 24, 2026 | Jay S Stout | Chief Technology Officer | Sale | 2.8K | $29.62 | $81.6K | SEC ↗ |
| Apr 10, 2026 | Christopher Van Tuyl | Chief Legal Officer | Sale | 5.2K | $24.83 | $128.2K | SEC ↗ |
Showing the 25 most recent of 204 Form 4 filings for Immunovant, Inc..
Most active IMVT insiders
- Peter Salzmann33 filings
- Eva Renee Barnett24 filings
- Julia G. Butchko24 filings
- William L. Macias21 filings
- Jay S Stout17 filings
Ask anything about IMVT insider activity
Use Trabud's AI agent to query Immunovant, Inc.'s Form 4 history in plain English — "Show me IMVT CEO purchases this year" or compare it against any other ticker.
Open the AI agentIMVT insider trading FAQ
Are Immunovant, Inc. insiders buying or selling?
In the last 12 months, Immunovant, Inc. insiders reported 1 open-market purchase ($350.0M) and 38 sales ($16.1M) — net buying of $333.9M. Since November 2019, Trabud has recorded 204 Form 4 filings for IMVT: 25 buys ($784.9M) and 179 sells ($42.3M). Over the full record that is net buying of $742.6M.
How many insiders trade IMVT stock?
19 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Immunovant, Inc.. The most recent filing was accepted on Oct 9, 2026.
Where does Trabud get IMVT insider trading data?
All IMVT insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.